Stay updated with breaking news from Cell Therapy Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive... | April 12, 2023
Recommendation for approval based on Phase 3 TRANSFORM study, supporting the potential of Breyanzi in earlier lines of therapy in this patient population ... | March 31, 2023
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of lisocabtagene maraleucel for the treatment of select patients with large B-cell lymphoma who relapsed within 12 months from completion of or developed refractory disease to frontline chemoimmunotherapy.
In a Phase III study, a CAR T-cell therapy more than tripled progression-free survival compared with standard care for multiple myeloma.
Topline results were announced from the TRANSCEND CLL 004 trial investigating lisocabtagene maraleucel for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.